SOUTH PLAINFIELD, N.J., July 23 -- ABLE LABORATORIES, INC. (Nasdaq: ABRX), today announced that it has received Food and Drug Administration approval for its Abbreviated New Drug Applications ("ANDAs") for Hydroxyzine Hydrochloride Tablets, USP 10mg, 25mg and 50mg, which are therapeutically equivalent to Hydroxyzine Hydrochloride Tablets, USP 10mg, 25mg and 50mg of Pliva, Inc. (formerly Sidmak Laboratories, Inc.). The total sales for Able's newly approved drugs (used in the treatment of both anxiety and tension associated with psychoneurosis and management of pruritis due to adverse allergic reactions), is estimated to be approximately $117 million according to recent market data.

Able, for 2004, has received 10 ANDA approvals to-date, five within the last two months.

Able Laboratories is a developer and manufacturer of generic pharmaceuticals. Further information on Able may be found on the Company's web site, http://www.ablelabs.com.

Except for historical facts, the statements in this news release, as well as oral statements or other written statements made or to be made by Able Laboratories, Inc., are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties. For example, statements about the Company's ability to formulate drug products, its operations and ability to increase sales and manage its growth, the expected effects of the Company's expansion of its production facilities, the current or expected market size for the Company's products, the adequacy of the Company's manufacturing capacity, the availability of sufficient capital, the success of current or future product offerings, research and development efforts and the Company's ability to file for and obtain U.S. Food and Drug Administration approvals for future products, are forward-looking statements. Forward-looking statements are merely the Company's current predictions of future events. The statements are inherently uncertain, and actual results could differ materially from the statements made herein. There is no assurance that the Company will continue to achieve the sales levels necessary to make its operations profitable or that its ANDA filings and approvals will be completed and obtained as anticipated. For a description of additional risks, and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2004 and its Annual Report on Form 10-K for the year ended December 31, 2003. The Company assumes no obligation to update its forward-looking statements to reflect new information and developments.